12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Remura low concentration bromfenac: Phase III started

Ista began a pair of double-blind, placebo-controlled, U.S. Phase III trials to evaluate 2 doses of Remura in about 1,000 patients with mild to moderate dry eye disease over 42 days. The company has an...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >